DDRE-31. Feasibility and Biologic Activity of a Ketogenic / Intermittent Fasting Diet in Glioma Patients

Schreck, Karisa; Hsu, Fang-Chi; Berrington, Adam; Henry-Barron, Bobbie; Vizthum, Diane; Blair, Lindsay; Kossoff, Eric; Easter, Linda; Whitlow, Christopher; Cervenka, Mackenzie; Barker, Peter; Blakeley, Jaishri; Strowd, Roy

Abstract

BACKGROUND
There has been increasing interest in exploring ketogenic diet therapies (KDT) in patients with glioma given the poor prognosis. The purpose of this single-arm, open label phase 2 study was to rigorously examine the feasibility, safety, systemic biological activity, and cerebral activity of a KDT in patients with glioma.

METHODS
25 patients with biopsy-confirmed WHO Grade 2–4 astrocytoma with stable disease following adjuvant chemotherapy were enrolled in an 8-week GLioma Atkins-based Diet (GLAD). GLAD consisted of 2 fasting days (calories

Citation

Schreck, K., Hsu, F.-C., Berrington, A., Henry-Barron, B., Vizthum, D., Blair, L., Kossoff, E., Easter, L., Whitlow, C., Cervenka, M., Barker, P., Blakeley, J., & Strowd, R. (2021). DDRE-31. Feasibility and Biologic Activity of a Ketogenic / Intermittent Fasting Diet in Glioma Patients. Neuro-Oncology Advances, 3(Supplement_1), i13-i13. https://doi.org/10.1093/noajnl/vdab024.053

• Journal Article Type: Article
• Acceptance Date: Jan 15, 2021
• Online Publication Date: Mar 25, 2021
• Publication Date: Mar 1, 2021
• Deposit Date: Jul 12, 2021
• Publicly Available Date: Jul 12, 2021
• Journal: Neuro-Oncology Advances
• Electronic ISSN: 2632-2498
• Publisher: Oxford University Press (OUP)
• Peer Reviewed: Peer Reviewed
• Volume: 3
• Issue: Supplement_1
• Pages: i13-i13
• DOI: https://doi.org/10.1093/noajnl/vdab024.053
• Public URL: https://nottingham-repository.worktribe.com/output/5689867
• Publisher URL: https://academic.oup.com/noa/article/3/Supplement_1/i13/6186373